Amgen to advance KRAS drug combination after improved results in colon cancer

Combining Amgen's KRAS-blocking drug Lumakras with an older targeted therapy appeared to result in a higher rate of treatment responses among patients with advanced colon cancer than was previously reported for Lumakras alone, spurring the biotech company to launch a larger Phase 3 trial of the drug pairing.